Stock GNLX GENELUX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Genelux Corporation

Equities

GNLX

US36870H1032

Delayed Nasdaq
Other stock markets
 03:59:54 2024-05-28 pm EDT 		5-day change 1st Jan Change
2.78 USD +6.11% Intraday chart for Genelux Corporation -44.42% -80.09%
May. 24 Top Midday Decliners MT
May. 24 Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Midday Decliners
MT
Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop
MT
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GL
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
AQ
Genelux Launches Securities Offering; Shares Fall After-Hours
MT
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
GL
Top Premarket Gainers
MT
Earnings Flash (GNLX) GENELUX CORPORATION Reports Q1 Revenue $8,000
MT
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
GL
Genelux Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Genelux Insider Sold Shares Worth $256,227, According to a Recent SEC Filing
MT
HC Wainwright Cuts Price Target on Genelux to $32 From $35, Maintains Buy Rating
MT
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Genelux Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Genelux Insider Sold Shares Worth $435,995, According to a Recent SEC Filing
MT
Genelux Says FDA Grants Fast Track Designation to Potential Ovarian Cancer Treatment Olvi-Vec
MT
HC Wainwright Initiates Genelux at Buy With $35 Price Target
MT
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
GL
Benchmark Company Adjusts Genelux Price Target to $30 From $38, Maintains Speculative Buy Rating
MT
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNLX Stock
  4. News Genelux Corporation